psm3mkv
An R package developed by Merck that helps compare different cost-effectiveness models in oncology using progression-free survival, overall survival, and time-to-progression data.
At a glance
Use when
Comparing model structures in oncology cost-effectiveness analyses using time-to-event data
Avoid when
Analyzing non-oncology conditions or models with more than three health states
Inputs
PFS, OS, and TTP data from oncology studies
Outputs
Model fit statistics, efficiency comparisons, and evaluation of structural assumptions across different three-state models
How it works
psm3mkv is an R package from Merck that fits and compares three-state oncology cost-effectiveness models, including partitioned survival models and clock-forward/clock-reset state-transition models, using PFS, OS, and TTP data to evaluate model fit, efficiency, and structural assumptions.
- HTA domains
- Clinical Effectiveness, Costs & Economic Evaluation
- Assumptions
- Disease progression and survival can be modeled using three-state structures; PFS/OS/TTP data are sufficient to inform model selection
- Strengths
- Enables direct comparison of multiple modeling approaches; supports evidence-based model selection in oncology cost-effectiveness
- Limitations
- Limited to three-state oncology models; requires high-quality PFS/OS/TTP data
Questions this answers
- › How do different three-state oncology models compare in terms of fit and efficiency?
- › What are the implications of structural assumptions in cost-effectiveness models?
- › How well do partitioned survival models perform compared to state-transition models in oncology?
- › Can PFS/OS/TTP data inform model selection?
- › What model structure best captures disease progression and survival outcomes?
- › How sensitive are results to model structure in oncology cost-effectiveness analyses?
References & sources
Similar by meaning
Beta record. Based on the original catalogue summary; primary-source enrichment pending.